Point-of-Care Testing MAKING A DIFFERENCE WITH RAPID MOLECUL AR TESTING The ID NOW™ molecular platform was designed as a true point-of-care device to improve decision-making processes in any setting. ID NOW™ COVID-19 Positive results in as little as 5 minutes and negative results in 13 minutes ID NOW™ INFLUENZA A & B 2 Results in 13 minutes or less, with early detection of positives in as little as 5 minutes ID NOW™ RSV Results in 13 minutes or less ID NOW™ STREP A 2 Results in 6 minutes or less, with early detection of positives in as little as 2 minutes The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. © 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. COL-04046-04 07/22 22MS6122 27 henryschein.com/medicalhttp://www.henryschein.com/medical